This may be the eye of the storm in a takeover skirmish between China’s privately-held Meinian Onehealth Healthcare and peer iKang Healthcare (KANG).
The two companies lead China’s bustling preventive health care market, which Forbes estimated near $9 billion in November. Both combine high-tech medical examinations and disease screening with traditional Chinese treatments.